Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 147

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 147
---
 restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and
other remuneration to health care professionals and entities.

Penalties for violation of
any of the health care laws described above or any other governmental regulations that apply to us include, without limitation, civil,
criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs,
such as Medicare and Medicaid, injunctions, refusal to allow us to enter into government contracts, contractual damages, reputational
harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of an entity’s operations

Employees

As of the date of this prospectus,
we have three members of our senior management that are engaged as external service providers and four part-time employees. In addition,
we have three part-time personnel engaged in research and development. We are not bound by any collective bargaining agreements. We consider
the relationship with our employees to be good. We also use outside consultants and contractors with special expertise and skills for
limited engagements, including manufacturing and quality assurance. We plan to contract with a contract research organization that
is knowledgeable and experienced in developing, testing and commercializing medical solutions.

<div align='center'>87</div>

Facilities

We do not have manufacturing
facilities. We operate out of our offices in Herzliya 4676652, Israel that are being provided for a monthly fee of $5,500 (including
$3,000 for administrative expenses). We expect to lease additional space as we expand the team upon conclusion of this offering.

Legal Proceedings

CSL Behring GmbH Payment Dispute

In 2019, a
controversy has arisen between us and CSL whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020
are to be paid by us pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the
Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, we received a termination letter, or
CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820,000, claiming it was owed the minimum
purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018 and 2019. In a subsequent
correspondence, CSL additionally demanded interest and damages for lost profit, with an